Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies

Volumn , Issue , 2015, Pages 41-58

  Suri, Krishna ^a   Wolfram, Joy ^a,b   Shen, Haifa ^a,c   Ferrari, Mauro ^a,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Biological barriers; Drug delivery; Nanomedicine; Nanotechnology; Nanotherapeutics

Indexed keywords

EID: 84939629086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-416603-5.00003-1     Document Type: Chapter

References (94)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
2. Ferrari, M. Clinical Cancer Nanotherapeutics, submitted.
3. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., Terada Y., Kano M.R., Miyazono K., Uesaka M., Nishiyama N., Kataoaka K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol 2011, 6:815-823.
4. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Ipe B.I., Bawendi M.G., Frangioni J.V. Renal clearance of quantum dots. Nat. Biotechnol 2007, 25:1165-1170.
5. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 2010, 15:171-185.
6. Wolfram J., Suri K., Celia C., Yang Y., Shen J., Fresta M., Zhao Y., Shen H., Ferrari M. Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf. B Biointerfaces 2014, 114:294-300.
7. Michor F., Liphardt J., Ferrari M., Widom J. What does physics have to do with cancer?. Nat. Rev. Cancer 2011, 11:657-670.
8. Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. Trends Biotechnol 2010, 28:181-188.
9. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
10. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
11. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54:3352-3356.
12. Gentile E., Cilurzo F., Di Marzio L., Carafa M., Ventura C.A., Wolfram J., Paolino D., Celia C. Liposomal chemotherapeutics. Future Oncol 2013, 912:1849-1859.
13. Li S.-D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release 2010, 145:178-181.
14. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl 2010, 49:6288-6308.
15. Chang H.-I., Yeh M.-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomed 2012, 7:49-60.
16. Celia C., Trapasso E., Locatelli M., Navarra M., Ventura C.A., Wolfram J., Carafa M., Morittu V.M., Britti D., Di Marzio L., Paolino D. Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells. Colloids Surf. B Biointerfaces 2013, 112:548-553.
17. Koudelka S., Turánek J. Liposomal paclitaxel formulations. J. Control. Release 2012, 163:322-334.
18. Menon C., Ghartey A., Canter R., Feldman M., Fraker D.L. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann. Surg 2006, 244:781-791.
19. Weis S.M. Vascular permeability in cardiovascular disease and cancer. Curr. Opin. Hematol 2008, 15:243-249.
20. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm. Res 2009, 26:235-243.
21. Longmire M.R., Ogawa M., Choyke P.L., Kobayashi H. Biologically optimized nanosized molecules and particles: more than just size. Bioconjugate Chem 2011, 22:993-1000.
22. Xiao K., Li Y., Luo J., Lee J., Xiao W., Gonik A., Agarwal R., Lam K. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
23. Chen H., Zhu H., Hu J., Zhao Y., Wang Q., Wan J., Yang Y., Xu H., Yang X. Highly compressed assembly of deformable nanogels into nanoscale suprastructures and their application in nanomedicine. ACS Nano 2011, 5:2671-2680.
24. Decuzzi P., Godin B., Tanaka T., Lee S.-Y., Chiappini C., Liu X., Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 2010, 141:320-327.
25. Van de Ven A.L., Kim P., Haley O., Fakhoury J., Adriani G., Schmulen J., Moloney P., Hussain F., Ferrari M., Liu X., Yun S.-H., Decuzzi P. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control. Release 2012, 158:148-155.
26. Adriani G., de Tullio M.D., Ferrari M., Hussain F., Pascazio G., Liu X., Decuzzi P. The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials 2012, 33:5504-5513.
27. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
28. Conlin A.K., Seidman A.D., Bach A., Lake D., Dickler M., D'Andrea G., Traina T., Danso M., Brufsky A., Saleh M., Clawson A., Hudis C. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin. Breast Cancer 2010, 10:281-287.
29. Hawkins M.J., Soon-Shiong P., Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev 2008, 60:876-885.
30. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res 2006, 12:1317-1324.
31. Ten Tije A.J., Verweij J., Loos W.J., Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet 2003, 42:665-685.
32. Yardley D.A. nab-Paclitaxel mechanisms of action and delivery. J. Control. Release 2013, 170:365-372.
33. Gradishar W.J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol 2005, 23:7794-7803.
34. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater 2012, 24:3747-3756.
35. Cardoso M.M., Peça I.N., Roque A.C.A. Antibody-conjugated nanoparticles for therapeutic applications. Curr. Med. Chem 2012, 19:3103-3127.
36. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 2008, 8:473-480.
37. Pollinger K., Hennig R., Ohlmann A., Fuchshofer R., Wenzel R., Breunig M., Tessmar J., Tamm E.R., Goepferich A. Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application. Proc. Natl. Acad. Sci. USA 2013, 110:6115-6120.
38. Sperling R.A., Parak W.J. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos. Trans. A Math Phys. Eng. Sci 2010, 368:1333-1383.
39. Wang A.Z., Gu F., Zhang L., Chan J., Radovic-Moreno A., Shaikh M., Farokhzad O. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther 2008, 8:1063-1070.
40. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U.S.A 2008, 105:14265-14270.
41. Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F., Hristov D., Kelly P., Aberg C., Mahon E., Dawson K. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol 2013, 8:137-143.
42. Gaspar R. Nanoparticles: pushed off target with proteins. Nat. Nanotechnol 2013, 8:79-80.
43. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol 2012, 7:779-786.
44. Mahon E., Salvati A., Baldelli Bombelli F., Lynch I., Dawson K.A. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J. Control. Release 2012, 161:164-174.
45. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov 2008, 7:771-782.
46. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C., Yen Y., Heidel J., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
47. Daniels T.R., Bernabeu E., Rodríguez J.A., Patel S., Kozman M., Chiappetta D., Holler E., Ljubimova J.Y., Helguera G., Penichet M. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 2012, 1820:291-317.
48. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med 2012, 4:128ra39.
49. Arap W. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
50. Hood J.D. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
51. Dias-Neto E., Nunes D.N., Giordano R.J., Sun J., Botz G., Yang K., Setubal J.C., Pasqualini R., Arap W., Ho P.L. Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS ONE 2009, 4:e8338.
52. Mann A.P., Tanaka T., Somasunderam A., Liu X., Gorenstein D.G., Ferrari M. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv. Mater 2011, 23:H278-282.
53. Glazer E.S., Zhu C., Massey K.L., Thompson C.S., Kaluarachchi W.D., Hamir A.N., Curley S.A. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin. Cancer Res 2010, 16:5712-5721.
54. Shen H., You J., Zhang G., Ziemys A., Li Q., Bai L., Deng X., Erm D.R., Liu X., Li C., Ferrari M. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv. Healthcare Mater 2012, 1:84-89.
55. Hirsch L.R., Stafford R.J., Bankson J.A., Sershen S.R., Rivera B., Price R.E., Hazle J.D., Halas N.J., West J.L. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. U.S.A 2003, 100:13549-13554.
56. Gobin A.M., Lee M.H., Halas N.J., James W.D., Drezek R.A., West J.L. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett 2007, 7:1929-1934.
57. Johannsen M., Thiesen B., Jordan A., Taymoorian K., Gnevecknow U., Waldofner N., Scholz R., Koch M., Lein M., Jung K., Loening S.A. Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 2005, 64:283-292.
58. Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H., Budach V., Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neuro-Oncol 2010, 103:317-324.
59. Chakravarty P., Marches R., Zimmerman N.S., Swafford A.D.E., Bajaj P., Musselman I.H., Pantano P., Draper R.K., Vitetta E.S. Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc. Natl. Acad. Sci. U.S.A 2008, 105:8697-8702.
60. Ghosh S., Dutta S., Gomes E., Carroll D., D'Agostino R., Olson J., Guthold M., Gmeiner W.H. Increased heating efficiency and selective thermal ablation of malignant tissue with DNA-encased multiwalled carbon nanotubes. ACS Nano 2009, 3:2667-2673.
61. Sharma A., Jain N., Sareen R. Nanocarriers for diagnosis and targeting of breast cancer. BioMed Res. Int 2013, 2013:1-10.
62. Cervadoro A., Giverso C., Pande R., Sarangi S., Preziosi L., Wosik J., Brazdeikis A., Decuzzi P. Design maps for the hyperthermic treatment of tumors with superparamagnetic nanoparticles. PLoS ONE 2013, 8:e57332.
63. Li L., ten Hagen T.L.M., Bolkestein M., Gasselhuber A., Yatvin J., van Rhoon G.C., Eggermont A.M.M., Haemmerich D., Koning G.A. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. J. Control. Release 2013, 167:130-137.
64. Li K.C.P., Pandit S.D., Guccione S., Bednarski M.D. Molecular imaging applications in nanomedicine. Biomed. Microdevices 2004, 6:113-116.
65. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 2011, 153:198-205.
66. Elbakry A., Wurster E.-C., Zaky A., Liebl R., Schindler E., Bauer-Kriesel P., Blunk T., Rachel R., Goepferich A., Breunig M. Layer-by-layer coated gold nanoparticles: size-dependent delivery of DNA into cells. Small 2012, 8:3847-3856.
67. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
68. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
69. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, 161:505-522.
70. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
71. Wong C., Stylianopoulos T., Cui J., Martin J., Chauhan V.P., Jiang W., Popovic Z., Jain R.K., Bawendi M.G., Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U.S.A 2011, 108:2426-2431.
72. Tanaka T., Decuzzi P., Cristofanilli M., Sakamoto J.H., Tasciotti E., Robertson F.M., Ferrari M. Nanotechnology for breast cancer therapy. Biomed. Microdevices 2009, 11:49-63.
73. Godin B., Gu J., Serda R.E., Bhavane R., Tasciotti E., Chiappini C., Liu X., Tanaka T., Decuzzi P., Ferrari M. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J. Biomed. Mater. Res. A 2010, 94:1236-1243.
74. Anglin E.J., Cheng L., Freeman W.R., Sailor M.J. Porous silicon in drug delivery devices and materials. Adv. Drug Deliv. Rev 2008, 60:1266-1277.
75. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res 2011, 44:979-989.
76. Xu R., Huang Y., Mai J., Zhang G., Guo X., Xia X., Koay E.J., Qin G., Erm D.R., Li Q., Liu X., Ferrari M., Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 2013, 9:1799-1808.
77. Blanco E., Sangai T., Hsiao A., Ferrati S., Bai L., Liu X., Meric-Bernstam F., Ferrari M. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 2013, 334:245-252.
78. 1 contrast. Nat. Nanotechnol 2010, 5:815-821.
79. Von Maltzahn G., Park J.-H., Lin K.Y., Singh N., Schwoppe C., Mesters R., Berdel W.E., Ruoslahti E., Sailor M.J., Bhatia S.N. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater 2011, 10:545-552.
80. Pawelek J.M., Low K.B., Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003, 4:548-556.
81. Yoo J.-W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov 2011, 10:521-535.
82. Akin D., Sturgis J., Ragheb K., Sherman D., Burkholder K., Robinson J.P., Bhunia A.K., Mohammed S., Bashir R. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nat. Nanotechnol 2007, 2:441-449.
83. Xu L., Frederik P., Pirollo K.F., Tang W.-H., Rait A., Xiang L.-M., Huang W., Cruz I., Yin Y., Chang E.H. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum. Gene Ther 2002, 13:469-481.
84. Kabanov A.V., Vinogradov S.V. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew. Chem. Int. Ed 2009, 48:5418-54129.
85. Lee E.S., Kim D., Youn Y.S., Oh K.T., Bae Y.H. A virus-mimetic nanogel vehicle. Angew. Chem. Int. Ed 2008, 47:2418-2421.
86. Parodi A., Quattrocchi N., van de Ven A.L., Chiappini C., Evangelopoulos M., Martinez J.O., Brown B.S., Khaled S.Z., Yazdi I.K., Enzo M.V., Isenhart L., Ferrari M., Tasciotti E. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol 2013, 8:61-68.
87. Dash A.K., Cudworth G.C. Therapeutic applications of implantable drug delivery systems. J. Pharmacol. Toxicol. Meth 1998, 40:1-12.
88. Liang X.-J., Chen C., Zhao Y., Wang P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer 2010, 467-488. Humana Press, Totowa, NJ. J. Zhou (Ed.).
89. Park H., Park K. Biocompatibility issues of implantable drug delivery systems. Pharm. Res 1996, 13:1770-1776.
90. Danckwerts M., Fassihi A. Implantable controlled release drug delivery systems: a review. Drug Dev. Ind. Pharm 1991, 17:1465-1502.
91. Staples M., Daniel K., Cima M.J., Langer R. Application of micro- and nano-electromechanical devices to drug delivery. Pharm. Res 2006, 23:847-863.
92. Grattoni A., Shen H., Fine D., Ziemys A., Gill J.S., Hudson L., Hosali S., Goodall R., Liu X., Ferrari M. Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration. Pharm. Res 2011, 28:292-300.
93. Sih J., Bansal S.S., Filippini S., Filippini S., Ferrati S., Raghuwansi K., Zabre E., Nicolov E., Fine D., Ferrari M., Palapattu G., Grattoni A. Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: new perspectives on promoting heart health. Anal. Bioanal. Chem 2013, 405:1547-1557.
94. Fine D., Grattoni A., Hosali S., Ziemys A., De Rosa E., Gill J., Medema R., Hudson L., Kojic M., Molosevic M., Brousseau I.L., Goodall R., Ferrari M., Liu X. A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery. Lab Chip 2010, 10:3074-3083.